Evidence map›Paper›PMID 40190814›Full record

ArticleDrug design, development and therapy2025

pH-Sensitive Porphyrin Metal-Organic Frameworks for Controlled Delivery of Para-Toluenesulfonamide and Photodynamic Cancer Therapy.

Wei Zhou, Fan Feng, Jieli Zhang, Shuang Cao, Yunzhi Zhou, Yanming Li

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei ZhouDepartment of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, 100730, People's Republic of China.
Fan FengClinical Laboratory, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, 100039, People's Republic of China.ORCID 0000-0001-8022-5514
Jieli ZhangDepartment of Respiratory and Critical Care Medicine, Emergency General Hospital, Beijing, 100028, People's Republic of China.ORCID 0009-0003-3387-9381
Shuang CaoSchool of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430205, People's Republic of China.ORCID 0000-0002-1855-3426
Yunzhi ZhouDepartment of Respiratory and Critical Care Medicine, Emergency General Hospital, Beijing, 100028, People's Republic of China.
Yanming LiDepartment of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, 100730, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Photodynamic therapy (PDT) is a promising approach for tumor treatment. PDT for treating lung squamous cell carcinoma (LSCC) under the guidance of bronchoscopy has great potential for development. However, the use of high-intensity lasers in treatment may pose a risk of tissue damage. To address this issue, enhancing the sensitivity of tumor tissue to phototherapy is highly valuable. Methods: In this study, a simple method was employed to prepare porphyrin-metal framework nanoparticles (NPs), referred to as HA-PTS@PCN. The design of these NPs is based on the concept of tumor sensitization, constructed with the porphyrin-based metal-organic framework compound PCN-224 to load the drug para-toluenesulfonamide (PTS). Results: Multiple experiments have demonstrated that these NPs can be effectively absorbed and selectively release PTS within the acidic tumor microenvironment. Under 660 nm laser irradiation, the material releases reactive oxygen species, demonstrating effective photodynamic therapeutic effects. Additionally, due to the tumor-sensitizing properties of PTS, the treatment efficacy of these NPs on LSCC is significantly greater than that of PCN-224 alone. Both in vitro and in vivo studies confirmed that combining tumor sensitization strategies with PDT therapy for LSCC significantly enhances anticancer effects. Discussion: This study provides a universal strategy for preparing drug-loaded PDT nanoplatforms and offers a new approach for developing nanomedicine with tumor-sensitizing effects.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellLung NeoplasmsMetal-Organic FrameworksPhotochemotherapyPhotosensitizing AgentsPorphyrinsSulfonamidesAnimalsBenzenesulfonamidesCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansHydrogen-Ion ConcentrationMice4-toluenesulfonamideAntineoplastic AgentsBenzenesulfonamidesMetal-Organic FrameworksPhotosensitizing AgentsPorphyrinsReactive Oxygen SpeciesSulfonamidesToluenemetal-organic frameworknanomedicinePDTPTStumor sensitization

Identifiers

PMID40190814
PMCPMC11971995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.